Aumolertinib and chemotherapy for EGFR L858R lung cancer
Part of Cancer clinical trials.
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic lung adenocarcinoma (stage IIIB, IIIC, or IV) that cannot be treated with surgery or radiation alone
- Your tumor has the EGFR L858R mutation (confirmed by a blood or tissue test)
- You have never received systemic chemotherapy or targeted therapy for advanced lung cancer (prior adjuvant treatments are okay if completed >12 months ago)
- Your overall health status allows you to care for yourself with minimal assistance (ECOG performance status 0–2) and your life expectancy is at least 3 months
- Your blood counts, liver, and kidney function are adequate (measured within 14 days before starting treatment)
- If you can have children, you agree to use highly effective contraception during and after the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
Hear when a new Lung Adenocarcinoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.